title: Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.
abstract: BACKGROUND
  Anaplastic thyroid cancer has a very poor prognosis, especially in patients who have gross residual disease following resection.
  
  
  METHODS
  We present the case of a patient with anaplastic thyroid cancer and a significant gross residual disease treated with intensity-modulated radiotherapy with concurrent chemotherapy and sunitinib who had a complete response and remains without evidence of disease more than 18 months after diagnosis.
  
  
  CONCLUSIONS
  Chemoradiotherapy has an important role in the adjuvant treatment of anaplastic thyroid cancer in selected patients and should be considered when gross residual disease is present following resection. The combined use of radiotherapy and targeted biological agents such as sunitinib may warrant further investigation.
authors.affiliation: Harvard Radiation Oncology Program, and Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. jdschoenfeld@partners.org
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Schoenfeld
authors.forename: Oreofe O
authors.initials: OO
authors.lastname: Odejide
authors.forename: Lori J
authors.initials: LJ
authors.lastname: Wirth
authors.forename: Annie W
authors.initials: AW
authors.lastname: Chan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D050397:Radiotherapy, Intensity-Modulated; D000077210:Sunitinib; D065646:Thyroid Carcinoma, Anaplastic; D013964:Thyroid Neoplasms / Q000401:mortality / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib